Bladder and Kidney Cancer Following Cyclophosphamide Therapy for Non-Hodgkin's Lymphoma
Lois B. Travis(Indiana University – Purdue University Indianapolis), J D Boice(National Cancer Institute), Rochelle E. Curtis(National Institutes of Health), Johanna Adami(Uppsala University Hospital), Peter D. Inskip(United States Department of Health and Human Services), F.E. van Leeuwen(The Netherlands Cancer Institute), Bengt Glimelius(Uppsala University), Peter M. Banks(National Cancer Institute), M. Gospodarowicz(Princess Margaret Cancer Centre), Eric J. Holowaty(Cancer Care Ontario), Marilyn Stovall(The University of Texas MD Anderson Cancer Center), A. Hagenbeek(Rotterdam University of Applied Sciences), Miriam Tucker(National Cancer Institute), C. F. Lynch(University of Iowa), Sholom Wacholder(National Cancer Institute)
Cited by 361
Related Papers
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
Assessing the Probability That a Positive Report is False: An Approach for Molecular Epidemiology Studies
|JNCI Journal of the National Cancer Institute|2004|1.8k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
|Nature Genetics|2007|1.5k
Replicating genotype–phenotype associations
|Nature|2007|1.4k